AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AtriCure Inc. (ATRC) PT Raised to $57 at BTIG
February 13, 2025 5:21 AM ESTBTIG analyst Marie Thibault raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $57.00 (from $53.00) while maintaining a Buy rating.
The analyst comments "AtriCure announced Q4 revenue of $124.3M (+16.6% y/y rep, +16.7% y/y cc), in line with the preliminary announcement last month. This result came in above the implied Q4 guidance range of $118M-$121M, beating consensus and our forecast of $119.8M at the time of the pre-announcement. U.S.... More
